Try our Advanced Search for more refined results
June 21, 2017
Track this case
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.Additional or older documents may be available in Pacer.
Sandoz Inc. has agreed to hold off on its generic version of Omeros Corp.’s cataract surgery drug Omidria until related patents expire in 15 years, putting an end to infringement litigation in Delaware federal court.
Already a subscriber? Click here to login